Comparison between Ocrevus vs Kesimpta
| Parameter | Ocrevus | Kesimpta |
|---|---|---|
| Class | Anti-CD20 | Anti-CD20 |
| Mechanism | B-cell depletion | B-cell depletion |
| Onset | Gradual | Gradual |
| Monitoring | None | None |
| Dosing | IV 6m | Monthly SC |
| Half-life | ~26 days | ~16 days |
| Reversal Agent | None | None |
| Bleeding Risk | Moderate | Moderate |
| Indications | MS | MS |
| Renal Use | Caution | Caution |
| Pregnancy Use | Avoid | Avoid |
| Drug Interactions | Moderate | Moderate |
| Adherence Sensitivity | Moderate | Moderate |
| Best Use Case | Infusion therapy | Home injection |
| Cost | High | High |
| Monitoring Burden | Low | Low |
| Clinical Flexibility | Moderate | Moderate |
| Real-world Convenience | Moderate | High |
| Overall Verdict | Infusion-based | Convenient |
| Food Interactions | None | None |